MetLife Investment Management’s Bioventus BVS Stock Holding History

MetLife Investment Management’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$282K	Buy	30,851 +3,340	+12%	+$28K	﹤0.01%	2041
2025 Q4	$205K	Hold	27,511	–	–	﹤0.01%	2262
2025 Q3	$184K	Hold	27,511	–	–	﹤0.01%	2366
2025 Q2	$182K	Buy	27,511 +5,113	+23%	+$36.3K	﹤0.01%	2243
2025 Q1	$205K	Sell	22,398 -583	-3%	-$5.82K	﹤0.01%	2188
2024 Q4	$241K	Hold	22,981	–	–	﹤0.01%	2207
2024 Q3	$275K	Buy	22,981 +12,949	+129%	+$112K	﹤0.01%	2123
2024 Q2	$57.7K	Buy	+10,032	New	+$55K	﹤0.01%	2736
2022 Q4	–	Sell	-18,975	Closed	-$133K	–	2832
2022 Q3	$133K	Hold	18,975	–	–	﹤0.01%	2539
2022 Q2	$129K	Hold	18,975	–	–	﹤0.01%	2590
2022 Q1	$268K	Buy	18,975 +6,917	+57%	+$92.6K	﹤0.01%	2168
2021 Q4	$175K	Buy	+12,058	New	+$171K	﹤0.01%	2139

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JIC

Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MetLife Investment Management's BVS Position: Q1 2026 in Review

MetLife Investment Management increased its Bioventus (BVS) stake by 12% in Q1 2026, buying an estimated $28K and bringing the position to 30,851 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

MetLife Investment Management first reported a position in BVS in Q4 2021 and has held it in 12 quarters since. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

MetLife Investment Management held 30,851 shares of Bioventus worth $282K as of Q1 2026.
MetLife Investment Management bought 3,340 Bioventus shares in Q1 2026, an estimated $28K.
Bioventus made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2041 holding.
MetLife Investment Management first reported a position in Bioventus in Q4 2021 and has held it in 12 quarters since.
157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.